ESMO 2021 | Final OS analysis from ARCHES

Silke Gillessen, MD, PhD, University of Lugano, Lugano, Switzerland and the Oncology Institute of Southern Switzerland, Bellinzona, Switzerland, discusses the final overall survival (OS) analysis from ARCHES (NCT02677896), a Phase III, randomized, double-blind, placebo-controlled study of enzalutamide and androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC). The combination of enzalutamide and ADT significantly prolongs survival in men with mHSPC and the results from ARCHES supports the clinical benefit of this combination. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.